Beijing Tiantan Biological Products Co., Ltd. (SHA:600161)
China
· Delayed Price · Currency is CNY 20.56
+0.18 (0.88%)
Mar 28, 2025, 3:00 PM CST
SHA:600161 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Operating Revenue | 6,032 | 5,162 | 4,244 | 4,112 | 3,434 | Upgrade
|
| Other Revenue | - | 18.38 | 16.86 | - | 11.28 | Upgrade
|
| Revenue | 6,032 | 5,180 | 4,261 | 4,112 | 3,446 | Upgrade
|
| Revenue Growth (YoY) | 16.43% | 21.57% | 3.63% | 19.35% | 4.99% | Upgrade
|
| Cost of Revenue | 2,732 | 2,553 | 2,172 | 2,159 | 1,751 | Upgrade
|
| Gross Profit | 3,299 | 2,628 | 2,089 | 1,954 | 1,695 | Upgrade
|
| Selling, General & Admin | 614.41 | 739.98 | 627.83 | 599.41 | 491.34 | Upgrade
|
| Research & Development | 142.79 | 139.95 | 122.01 | 133.21 | 118.61 | Upgrade
|
| Other Operating Expenses | 20.96 | 42.37 | 44.92 | 47.06 | 36.06 | Upgrade
|
| Operating Expenses | 778.16 | 921.65 | 796.02 | 779.55 | 646.18 | Upgrade
|
| Operating Income | 2,521 | 1,706 | 1,293 | 1,174 | 1,049 | Upgrade
|
| Interest Expense | - | -3.65 | -2.41 | -3.09 | -2.98 | Upgrade
|
| Interest & Investment Income | 63.93 | 92.74 | 90.19 | 80.92 | 35.86 | Upgrade
|
| Currency Exchange Gain (Loss) | - | 0 | 0.01 | -0 | -0.13 | Upgrade
|
| Other Non Operating Income (Expenses) | 15.01 | -5.01 | -0.7 | -3.05 | -1.22 | Upgrade
|
| EBT Excluding Unusual Items | 2,600 | 1,790 | 1,380 | 1,249 | 1,080 | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.04 | -1.04 | 13.55 | -0.3 | -0.62 | Upgrade
|
| Asset Writedown | -53.02 | -0.22 | -0.03 | -14.28 | -0.06 | Upgrade
|
| Other Unusual Items | - | 9.65 | 32.63 | 6.77 | 25.18 | Upgrade
|
| Pretax Income | 2,547 | 1,799 | 1,426 | 1,241 | 1,105 | Upgrade
|
| Income Tax Expense | 434.95 | 289.14 | 221.6 | 172.2 | 161.8 | Upgrade
|
| Earnings From Continuing Operations | 2,112 | 1,509 | 1,205 | 1,069 | 943.08 | Upgrade
|
| Minority Interest in Earnings | -563.1 | -399.57 | -323.76 | -308.8 | -304.07 | Upgrade
|
| Net Income | 1,549 | 1,110 | 880.92 | 760.01 | 639.01 | Upgrade
|
| Net Income to Common | 1,549 | 1,110 | 880.92 | 760.01 | 639.01 | Upgrade
|
| Net Income Growth | 39.58% | 25.99% | 15.91% | 18.94% | 4.57% | Upgrade
|
| Shares Outstanding (Basic) | 1,986 | 1,988 | 1,994 | 1,940 | 1,806 | Upgrade
|
| Shares Outstanding (Diluted) | 1,986 | 1,988 | 1,994 | 1,940 | 1,806 | Upgrade
|
| Shares Change (YoY) | -0.09% | -0.32% | 2.79% | 7.41% | 0.59% | Upgrade
|
| EPS (Basic) | 0.78 | 0.56 | 0.44 | 0.39 | 0.35 | Upgrade
|
| EPS (Diluted) | 0.78 | 0.56 | 0.44 | 0.39 | 0.35 | Upgrade
|
| EPS Growth | 39.71% | 26.40% | 12.77% | 10.73% | 3.95% | Upgrade
|
| Free Cash Flow | -247.63 | 1,316 | -228.02 | -151.35 | 93.2 | Upgrade
|
| Free Cash Flow Per Share | -0.13 | 0.66 | -0.11 | -0.08 | 0.05 | Upgrade
|
| Dividend Per Share | - | 0.125 | 0.042 | 0.069 | 0.069 | Upgrade
|
| Dividend Growth | - | 199.76% | -39.91% | - | 99.42% | Upgrade
|
| Gross Margin | 54.70% | 50.72% | 49.02% | 47.51% | 49.19% | Upgrade
|
| Operating Margin | 41.80% | 32.93% | 30.34% | 28.55% | 30.44% | Upgrade
|
| Profit Margin | 25.68% | 21.43% | 20.67% | 18.48% | 18.55% | Upgrade
|
| Free Cash Flow Margin | -4.11% | 25.40% | -5.35% | -3.68% | 2.71% | Upgrade
|
| EBITDA | 2,834 | 1,951 | 1,452 | 1,313 | 1,182 | Upgrade
|
| EBITDA Margin | 46.98% | 37.67% | 34.07% | 31.92% | 34.29% | Upgrade
|
| D&A For EBITDA | 312.55 | 245.36 | 158.74 | 138.65 | 132.75 | Upgrade
|
| EBIT | 2,521 | 1,706 | 1,293 | 1,174 | 1,049 | Upgrade
|
| EBIT Margin | 41.80% | 32.93% | 30.34% | 28.55% | 30.44% | Upgrade
|
| Effective Tax Rate | 17.08% | 16.08% | 15.54% | 13.88% | 14.64% | Upgrade
|
| Revenue as Reported | - | 5,180 | 4,261 | 4,112 | 3,446 | Upgrade
|
| Advertising Expenses | - | 1.63 | 5.26 | 6.35 | 7.41 | Upgrade
|
Updated Oct 25, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.